GLPwatch
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
NCT00308139 · Completed
Last updated 2026-05-28This clinical trial tested the effects of a long-acting diabetes medication called Exenatide on blood sugar control in adults with type 2 diabetes over 30 weeks.
Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 303 people
Who can join Ages 16+ · all sexes
Timeline Started 2006-04 · est. completion 2014-08
Where 25 sites · Canada, United States
What this study is testing ClinicalTrials.gov NCT00308139 ↗
Description as written by the study sponsor.
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.
Treatments tested
- exenatide, long acting release also known as BYDUREON Drug
- exenatide also known as Byetta Drug
| Main thing measured | Change in HbA1c From Baseline to Week 30 |
|---|---|
| Sponsor | AstraZeneca |
| Conditions studied | Type 2 Diabetes Mellitus |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00308139 ↗